Childhood maltreatment, prefrontal-paralimbic gray matter volume, and substance use in young adults and interactions with risk for bipolar disorder

Dylan E. Kirsch1,2,3, Valeria Tretyak1,2,4, Sepeadeh Radpour2, Wade A. Weber1, Charles B. Nemeroff1,2,4, Kim Fromme2,4, Stephen M. Strakowski1,2,3,4 & Elizabeth T. C. Lippard1,2,3,4,5

Childhood maltreatment is associated with adverse effects on the brain, and an increased risk for psychopathology, including mood and substance use disorders. Individuals vary on the degree to which they exhibit neurobiological and clinical differences following maltreatment. Individuals with bipolar disorder exhibit greater magnitude of maltreatment-related prefrontal-paralimbic gray matter volume (GMV) deficits compared to typically developing individuals. It is unclear if greater structural differences stem from greater neural vulnerability to maltreatment in bipolar disorder, or if they relate to presence of other clinical features associated with childhood maltreatment, e.g., elevated prevalence of comorbid substance use disorders. To investigate this, we compared young adults with a family history of bipolar disorder (n = 21), but who did not fulfill diagnostic criteria for bipolar disorder, with typically developing young adults without a family history of bipolar disorder (n = 26). Participants completed structural neuroimaging, clinical and family history interviews, and assessment of childhood maltreatment and recent alcohol and cannabis use patterns. We examined relations between childhood maltreatment and prefrontal-paralimbic GMV by modeling main effects of maltreatment and family history group by maltreatment interactions on prefrontal-paralimbic GMV. We also examined relations between maltreatment and associated GMV changes with recent alcohol and cannabis use. Childhood maltreatment correlated with lower ventral, rostral and dorsolateral prefrontal and insular cortical GMV across all participants regardless of the presence or absence of familial history of bipolar disorder. However, exploratory analyses did reveal greater maltreatment-related GMV differences in individuals with prodromal symptoms of depression. Lower insula GMV was associated with greater frequency of cannabis use across all participants and greater quantity of alcohol use only in those with familial risk for bipolar disorder. Results suggest familial risk for bipolar disorder, and presumably genetic risk, may relate to outcomes following childhood maltreatment and should be considered in prevention/early intervention strategies.

Early life stress (ELS), including childhood maltreatment, increases risk for a wide range of major psychiatric disorders, including bipolar disorder1,2. High rates of ELS are reported in individuals with both bipolar disorder, with estimates of ELS prevalence as high as 57%3. ELS has been related to neural changes that likely increase risk for bipolar disorder. Structural brain abnormalities in prefrontal-paralimbic systems observed following ELS are similar to structural abnormalities reported in bipolar disorder4-6. As individuals vary to the degree to which they exhibit neurobiological differences associated with ELS7, it is critical to identify factors that may contribute to variability in these neurobiological differences, and associated clinical outcomes.

1Department of Psychiatry and Behavioral Sciences, Dell Medical School, University of Texas at Austin, 1601 Trinity Street, Stop Z0600, Health Discovery Building, Austin, TX 78712, USA. 2Waggoner Center for Alcohol and Addiction Research, University of Texas, Austin, TX, USA. 3Institute for Neuroscience, University of Texas, Austin, TX, USA. 4Department of Psychology, University of Texas, Austin, TX, USA. 5Institute of Early Life Adversity Research, University of Texas, Austin, TX, USA. *email: elizabeth.lippard@austin.utexas.edu
Studies have suggested greater structural abnormalities associated with ELS in individuals with bipolar disorder, compared to healthy adults, including greater magnitude of gray matter volume (GMV) differences in prefrontal-paralimbic systems (e.g., ventral prefrontal and insular cortices). Greater structural changes exhibited in prefrontal-paralimbic regions following ELS in bipolar disorder may be related to prevalent severity of ELS observed in this population or to other disease-related factors that may alter prefrontal-paralimbic structure (e.g., medication exposure or disease-related GMV loss). As prior work has suggested ELS interacts with family history of unipolar depression to influence brain structure, findings could converge to suggest greater vulnerability of prefrontal-paralimbic systems to ELS in bipolar disorder, perhaps stemming from genetic factors that contribute to risk for bipolar disorder. No study has addressed whether ELS interacts with family history of bipolar disorder (and hence presumed genetic vulnerability) to impact prefrontal-paralimbic structures.

ELS also increases risk for substance use disorders (SUDs), including alcohol use disorders (AUDs), and ELS is associated with higher prevalence of comorbid SUDs in bipolar disorder, compared to prevalence of SUDs in healthy adults. Substance use has been suggested to be an intermediate step between ELS and bipolar disorder, and greater GMV differences following ELS in bipolar disorder may relate to high rates of SUDs in this population. Genes that confer risk for bipolar disorder may also increase risk for SUDs, however, it is unknown if familial risk for bipolar disorder interacts with ELS and associated brain changes to contribute to substance use during young adulthood, further structural brain changes following ELS, and ultimately risk for the development of bipolar disorder, SUDs, and their comorbidity.

The current study sought to determine if ELS interacts with familial risk for bipolar disorder to contribute to differences in neural structure of prefrontal-paralimbic systems, and if ELS and related neural differences relate to current substance use patterns in young adults. We hypothesized an interaction between ELS, specifically childhood maltreatment, and familial risk for bipolar disorder on prefrontal-paralimbic GMV. Additionally, we hypothesized childhood maltreatment and maltreatment-related GMV differences would be associated with substance use, with the familial risk subgroup showing a stronger association. We recruited young adults with first-degree family member(s) diagnosed with bipolar disorder, but who themselves did not fulfill diagnostic criteria for bipolar disorder (FH+), and a group of typically developing young adults without a first-degree family member diagnosed with bipolar disorder (FH-). Participants completed clinical and family history interviews, including assessment of childhood maltreatment and recent alcohol and cannabis use, and structural magnetic resonance imaging (MRI) scans. In this preliminary study, ELS-related differences in GMV within prefrontal-paralimbic a priori regions of interest (ROIs) were modeled across all participants, and interactions with familial risk for bipolar disorder were investigated. ROIs included the insular and ventral, dorsal, and rostral prefrontal cortices. Lower GMV in these regions have been reported following childhood maltreatment and found to distinguish individuals with bipolar disorder who prospectively develop alcohol and cannabis use problems. Based on our hypothesis, we predicted childhood maltreatment would inversely correlate with GMV in prefrontal-paralimbic regions, with greater GMV differences in the FH+, compared to in the FH- group. We also predicted childhood maltreatment and maltreatment-related prefrontal-paralimbic GMV differences would show an inverse relation with past month alcohol and cannabis use, with greater childhood maltreatment and greater maltreatment-related reductions in GMV associated with greater substance use in the FH+ group, compared to the FH- group. As individuals in the FH+ group presumably vary in their inherited risk for bipolar disorder, we also conducted an exploratory analysis aiming to determine if differences in maltreatment-related GMV exist within the FH+ group. Specifically, we investigated differences between FH+ individuals with prodromal depression history, compared to FH+ individuals without prodromal depression history, because higher polygenic risk for bipolar disorder is associated with unipolar depression in youth with familial risk for bipolar disorder.

**Methods and materials**

**Participants.** Participants included 47 young adults (21 FH+, 26 FH-). Table 1 details demographic, and familial characteristics stratified by group (FH+, FH-). Exclusion criteria included a diagnosis of bipolar disorder, major medical or neurological illness, including head injury with loss of consciousness for ≥5 min, an IQ <85, or other MRI contraindications. Participants with familial risk for bipolar disorder were not excluded if they had a history of unipolar depression or an anxiety disorder because depression and anxiety are considered prodromal symptoms of, and risk factors for, both bipolar disorder and SUDs. Additionally, across all participants, a history of SUDs was not an exclusion factor to facilitate recruiting a generalizable sample and to explore relations among maltreatment, related prefrontal-paralimbic system GMV, and recent alcohol and cannabis use patterns. As familial risk for bipolar disorder and other psychopathology (e.g., familial risk for SUDs) often coincide, FH- participants were not excluded for a family history of non-bipolar disorder psychiatric conditions (e.g., depression, anxiety, ADHD, and alcohol/substance use problems) to help account for additional familial psychopathology risk factors present in the FH+ group and to facilitate recruiting a FH- group with greater similarity in prevalence of childhood maltreatment to the FH+ group.

Current and lifetime psychiatric diagnoses and clinical characteristics were obtained using the Structured Clinical Interview for DSM-V-Research Version. Verbal comprehension and matrix reasoning subtests of the Wechsler Abbreviated Scale of Intelligence—Second Edition (WASI-II) were used as a measure of intelligence quotient (IQ; FSIQ). Family history of bipolar disorder, depression, anxiety, attention deficit hyperactivity disorder (ADHD), alcohol and substance use disorders was assessed using the Family History—Research Diagnostic Criteria—Epidemiological Version. All study procedures were approved by the University of Texas at Austin Institutional Review Board, and written informed consent was obtained from all participants. All methods were performance in accordance with the relevant guidelines and regulations. Participants were instructed to abstain from alcohol and drug use for 24 h before their scan. On the day of the scan, urine screens were administered...
to test for pregnancy and substances of abuse. Four participants (1 FH+, 3 FH−) had positive drug tests (see Table 1 for urine toxicology results).

### Assessment of childhood maltreatment and alcohol/cannabis use

#### Childhood maltreatment

All individuals completed the Childhood Trauma Questionnaire (CTQ), a 28-item retrospective self-report test measuring five subtypes of maltreatment (emotional abuse and neglect, physical abuse and neglect, and sexual abuse). A total CTQ score was obtained by summing the five maltreatment subtype scores. Total CTQ score was used as a continuous measure based on prior research suggesting childhood trauma exhibits a dose-dependent association between multiple types of trauma types on both neuroimaging findings and clinical outcomes. Table 1 details childhood maltreatment characteristics stratified by groups (FH+, FH−).

#### Alcohol/cannabis use

The Timeline Follow Back was used to obtain daily reports of alcohol and cannabis use for four weeks prior to the date of MRI assessment. Using a calendar marked with holidays and specific days, participants reported which days they consumed alcohol and cannabis and the number of standard drinks they consumed.

---

**Table 1.** Demographic, childhood maltreatment, and familial characteristics stratified by group. Entire sample [bipolar disorder family history negative (FH−) vs. bipolar disorder family history positive (FH+)] and FH+ subgroup [FH+ individuals without a history of unipolar depression (FH+DEP) vs. FH+ individuals with a history of unipolar depression (FH+ DEP+)] between-group differences in age, IQ, and CTQ were compared using a two-sample t-test. All other factors were examined with a Mann–Whitney Wilcoxon Test, Chi-square, or Fisher Exact tests, as appropriate. 1FSIQ-2 represents the composite score for the full-scale intelligence quotient comprising verbal comprehension and matrix reasoning subtests on the Wechsler Abbreviated Scale of Intelligence-Second Edition (WASI-II). 2Childhood Trauma Questionnaire. 3No individuals presented with comorbid AUD and SUD. 4Anxiety disorders included generalized anxiety disorder, specific phobia, panic disorder, and social anxiety disorder. 5Individual who tested positive for amphetamines also tested positive for tetrahydrocannabinol. URepresents p-values calculated with Mann–Whitney Wilcoxon Test. FRepresents p-values calculated with Fisher exact test.
metric Mapping-12 (SPM12, http://www.fil.ion.ucl.ac.uk/spm) was used to pre-process structural data with the without gap and one average. All scans were assessed visually for movement and noise artifacts. Statistical Para-

Neuroimaging data analysis: CTQ relations to prefrontal-paralimbic gray matter volume. For primary hypo-
thesis testing, SPM12 was used to model the relation between total CTQ score and prefrontal-paralimbic GMV in a priori hypothesized ROIs (insular and ventral, dorsal, and rostral prefrontal cortices) across all participants, with group (FH+, FH–) and sex as covariates. Sex was included as a covariate due to established sex-differences in the variables of interest. Findings within a priori ROIs were considered significant at p < 0.005 (uncorrected) and clusters ≥ 20 voxels. This threshold was chosen to balance type I and type II errors in preliminary studies as previously described. Group (FH+, FH–) by CTQ interactions on GMV, covarying sex, were modeled in SPM12. Mean GMV from clusters showing a significant relation with total CTQ across all participants and from clusters showing significant group by CTQ interactions was calculated and extracted. For clusters showing a significant group by CTQ interaction, relations between CTQ total score and extracted GMV were modeled stratified by group, while covarying sex, to investigate group differences driving a significant interaction. Studies have shown greater severity of childhood maltreatment is associated with more severe neural outcomes. Therefore, following a significant interaction, a sensitivity analysis was conducted with extracted GMV to assess group by CTQ interactions after removing four FH+ individuals with the highest CTQ scores and four FH– individuals with lowest CTQ scores so that groups (FH+ vs. FH–) did not differ in terms of average CTQ score and CTQ score range would be similar between groups.

Neuroimaging data analysis: childhood maltreatment and associated prefrontal-paralimbic gray matter volume relations with alcohol/cannabis use patterns. Alcohol and cannabis use measures were not normally distributed (Shapiro Wilke test, p < 0.05); therefore, a logarithmic transformation was applied to these measures. Across all

| Variable                        | FH– (N = 25) | FH+ (N = 17) | p value | FH+DEP– (N = 7) | FH+DEP+ (N = 10) | p value |
|---------------------------------|-------------|-------------|---------|----------------|-----------------|--------|
| Recent alcohol use              |             |             |         |                |                 |        |
| Maximum number of drinking days/week (SD) | 1.8 (1.5)  | 1.8 (1.8)  | 0.8     | 2.2 (0.9)      | 1.4 (1.2)       | 0.4    |
| Average number of drinks/drinking day (SD) | 2.3 (2.4)  | 2.1 (1.7)  | 0.8     | 1.5 (1.5)      | 2.5 (1.8)       | 0.7    |
| Recent cannabis use             |             |             |         |                |                 |        |
| Maximum number of cannabis use days/week (SD) | 2 (1.7)    | 2.4 (1.4)  | 0.6     | 3.5 (0.7)      | 2 (0.6)         | 0.3    |

Table 2. Past month alcohol and cannabis use. Past month alcohol use [mean and standard deviation (SD)] stratified by group [bipolar disorder family history negative (FH–) vs. bipolar disorder family history positive (FH+) individuals who completed the Timeline Follow Back and reported lifetime alcohol use] and FH+ subgroups (FH+ individuals without a history of unipolar depression (FH+DEP–) vs. FH+ individuals with a history of unipolar depression (FH+DEP+)] who completed the Timeline Follow Back and reported lifetime alcohol use. Past month cannabis use stratified by group in individuals who completed the Timeline Follow Back and reported past month cannabis use. Between group differences were calculated using Mann–Whitney Wilcoxon Tests.

consumed on these days. Recent alcohol use was quantified by determining maximum number of drinking days per week and average number of drinks per drinking day over the prior four weeks. Recent cannabis use was quantified by determining maximum number of cannabis use days per week over the prior four weeks. Table 2 details recent alcohol and cannabis use stratified by group. Participants were also asked at what age they initiated alcohol use (i.e. age of first drink, not just a sip from an adult’s glass, and not including drinking as part of religious ceremonies).

Structural neuroimaging: magnetic resonance imaging acquisition and preprocessing. All imaging was performed with a single 3-T Siemens Skyra MR scanner using a 32-channel head coil located at the University of Texas at Austin Biomedical Imaging Center (UT BIC). Sagittal structural MRI images were acquired with a three-dimensional MPRAGE T1-weighted sequence with parameters: repetition time (TR) = 1900 ms, echo time (TE) = 2.42 ms, matrix = 224 × 224, field of view = 220 × 220 mm², 192 one-mm slices without gap and one average. All scans were assessed visually for movement and noise artifacts. Statistical Parametric Mapping-12 (SPM12, http://www.fil.ion.ucl.ac.uk/spm) was used to pre-process structural data with the DARTEL toolbox in SPM12 as previously described.
participants who completed the Timeline Follow Back and reported lifetime alcohol use (N = 42; 17 FH+, 25 FH−), relations between total CTQ with recent alcohol use were investigated, with sex, group (FH+, FH−), and age of alcohol initiation included as covariates. Group (FH+ vs. FH−) by total CTQ interactions, covarying sex and age of alcohol initiation, were also modeled with alcohol use measures as the dependent variables. Age of alcohol initiation was included as a covariate because childhood maltreatment is associated with earlier age of alcohol initiation48, earlier initiation is associated with greater alcohol use37–39, and earlier initiation is associated with family history of problematic alcohol and other substance use40, which is commonly observed in individuals with familial risk for bipolar disorder. Following a significant interaction, relations between total CTQ and alcohol use were modeled within each group, covarying sex and age of alcohol initiation, to investigate group differences driving a significant interaction. The relation between total CTQ and recent cannabis use was explored in individuals who reported past month cannabis use, with sex and group included as covariates. Analysis was not conducted across the entire sample and interactions with group were not investigated for cannabis use owing to sample size (only 13 (28%) of participants reported smoking cannabis over the past month (FH+: N = 7; FH−: N = 6]). Parallel models were conducted, as described above, except with extracted GMV (from regions that showed a significant association with maltreatment) as the independent variable and alcohol and cannabis use as the dependent variables. Results were considered significant at p ≤ 0.05 uncorrected for these planned analyses. All significant findings are reported below.

Exploratory analyses: FH+ subgroups. In an exploratory analysis, the FH+ group was stratified into two subgroups: FH+ with a history of depression (FH+DEP+, N = 12) and FH+ without a history of depression (FH+DEP−, N = 9) to explore effects of childhood maltreatment in a presumably higher genetic risk group. History of depression was defined as having met criteria for a past major depressive episode on the Structured Clinical Interview for DSM-V-Research Version. Between group differences in demographics, childhood maltreatment, familial characteristics, and alcohol/cannabis use patterns were investigated, as described above. Table 1 details demographic, childhood maltreatment, and familial characteristics stratified by family history subgroup (FH+DEP+, FH+DEP−). Table 2 details recent alcohol and cannabis use stratified by family history subgroup. FH+ subgroup (FH+DEP+, FH+DEP−) by CTQ interactions on GMV, covarying sex, were modeled in SPM12, as described above. Mean GMV from clusters showing a significant group (FH+DEP+ vs. FH+DEP−) by CTQ interactions was calculated and extracted. Relations between CTQ total score and extracted GMV were modeled stratified by group, while covarying sex, to investigate group differences driving a significant interaction. Also as described above, following a significant interaction, a sensitivity analysis was conducted with extracted GMV to assess group by CTQ interactions after removing four FH+DEP+ individuals with the highest CTQ scores so that groups (FH+DEP+ vs. FH+DEP−) did not differ in terms of average CTQ score and CTQ score range would be similar between groups (see Supplemental Table 1 for comparison of matched FH+ subgroups).

Results
Between-group differences in demographic, childhood maltreatment, and familial characteristics, and alcohol/cannabis use patterns. CTQ total scores were higher in the FH+ group, compared to the FH− group (p < 0.001). The FH+, compared to the FH− group, had more individuals with a personal past history of unipolar depression (p < 0.001) and an anxiety disorder (p = 0.002), and higher prevalence of family history of an anxiety disorder (p = 0.01) and alcohol and substance use problems (both: p < 0.001). See Table 1 for information regarding differences in participant demographics, childhood trauma, and family history characteristics. Groups did not differ in recent alcohol or cannabis use. See Table 2 for information regarding differences in participant alcohol and cannabis use patterns.

Neuroimaging analysis. CTQ relations to prefrontal-paralimbic gray matter volume. As shown in Fig. 1, greater total CTQ scores correlated with lower GMV in two clusters in ventral prefrontal cortex (Brodmann Area [BA] 11, Montreal Neurological Institute [MNI] space coordinates: x = 3 mm, y = 27 mm, z = 24 mm, cluster = 141 voxels; BA47, x = − 39 mm, y = 27 mm, z = − 14 mm, cluster = 53 voxels), a cluster in left insula (x = − 32 mm, y = 24 mm, z = 5 mm, cluster = 150 voxels), a cluster in left rostral prefrontal cortex (BA10, x = − 26 mm, y = 47 mm, z = 24 mm, cluster = 114 voxels), and two clusters in bilateral dorsolateral prefrontal cortex (BA9, x = 26 mm, y = 47 mm, z = 29 mm, cluster = 203 voxels; x = − 23 mm, y = 45 mm, z = 42 mm, cluster = 754 voxels) across all young adults. No significant group by CTQ score interactions on GMV in prefrontal-paralimbic ROIs were observed when comparing FH+ and FH− groups.

Childhood maltreatment and associated prefrontal-paralimbic gray matter volume: relations with alcohol/cannabis use patterns. There was a family history group (FH+ vs. FH−) by insula GMV interaction on average number of drinks consumed per drinking day over the past four weeks (p = 0.03). Stratifying by group revealed a negative relation between insula GMV and average number of drinks per drinking day in the FH+ group (p = 0.02), but not in the FH− group (p = 0.7). See Table 3 for model statistics. Additionally, when examining relations between CTQ and associated GMV with alcohol use across all participants, age of alcohol initiation was inversely related to average number of drinks per drinking day and maximum number of drinking days per week (p = 0.01). Across all individuals who reported past month cannabis use, lower insula GMV significantly correlated with greater maximum number of cannabis use days per week. CTQ was not related to recent alcohol or cannabis use when looking across all participants, and there was no CTQ by group interaction on substance use.

Exploratory analysis: FH+ subgroups. CTQ scores were higher in the FH+DEP+ group compared to the FH+DEP− group (p = 0.01) (Table 1). FH+ subgroups did not differ in recent alcohol or cannabis use (Table 2).
Within the FH+ group, there was a significant subgroup (FH+DEP+, FH+DEP−) by CTQ interaction on GMV in the ventral extending to rostral and dorsal prefrontal, and insular cortex (Fig. 2A). See Table 4 for cluster details and post hoc modeling results. Post hoc analyses revealed that higher CTQ scores correlated with lower GMV in the FH+DEP+ group, and conversely associated with greater GMV, or no significant correlation, in the FH+DEP− group. Modeling the interaction after removing the four FH+DEP+ individuals with highest CTQ scores revealed a similar group by CTQ interaction on GMV in the ventral extending to rostral and dorsal prefrontal, and insular cortex. Figure 2B shows significant FH+ subgroup (FH+DEP+, FH+DEP−) by CTQ interaction after removing four individuals with the highest CTQ score in the FH+DEP+ subgroup.

**Discussion**

Results from this preliminary study suggest a history of childhood maltreatment is related to lower prefrontal ventral, rostral, and dorsal prefrontal, and insular cortical GMV in young adults, as previously reported. We predicted familial risk for bipolar disorder, and hence presumably genetic vulnerability, would be associated with greater magnitude of GMV differences. Although this prediction was not supported, in an exploratory analysis we did observe a significant interaction between familial risk for bipolar disorder subgroups (i.e. those already expressing depressive symptoms versus those not) and childhood maltreatment on GMV. The additional requirement of the presence of mood symptoms may refine the FH+ group to one enriched for higher genetic risk, because the majority of individuals with parental risk for bipolar disorder do not develop illness, and...
presumably do not inherit the necessary genetic risk profile. Additionally, lower insula GMV was associated with greater number of average drinks consumed per drinking day, with this relationship only observed in individuals with familial risk for bipolar disorder. Lower insula GMV was also associated with greater frequency of cannabis use across all participants. Although preliminary, these findings could suggest that greater maltreatment-related structural changes—previously observed in bipolar disorder—may emerge over time, following alcohol/cannabis misuse, and be related to genetic vulnerability for bipolar disorder. This preliminary study supports further research on the interactions between childhood maltreatment, family history (focusing on genetically enriched subgroups), and substance use on long-term neural and clinical outcomes.

The prefrontal cortex and insula are highly sensitive to the effects of stress, with childhood and adolescence marking a period of increased vulnerability to environmentally triggered insults due to the prolonged maturation of these regions during this developmental epoch. In line with our findings, previous studies have consistently shown childhood maltreatment-related reductions in the prefrontal cortex, especially within the ventral and dorsolateral prefrontal cortex, and insula GMV in typically developing and psychiatric populations. The prefrontal cortex, both ventral and dorsolateral components, and the insula contribute to emotional regulation, impulse control, and risky decision-making, with disruption in these processes thought to contribute to risk for the development of SUDs. Whereas this cross-sectional study cannot specify who will develop alcohol/cannabis use problems, a recent longitudinal study found that lower prefrontal, including ventral, rostral and dorsolateral prefrontal cortex, and insula GMV distinguished individuals with bipolar disorder who subsequently developed alcohol/cannabis use problems. These findings are concordant with our preliminary results—suggesting variation in insula GMV, particularly in individuals with familial risk for bipolar disorder, may be associated with greater alcohol/cannabis use—and support that structural changes within these regions following ELS may increase risk for alcohol/cannabis use problems. Additionally, alcohol use, even when consumed at moderate levels, has been associated with greater bipolar illness severity. Therefore, understanding how brain structure relates to moderate alcohol use (and vice versa) in individuals at risk for bipolar disorder may improve our understanding of mechanisms that contribute to mood symptom onset and progression. Our results further suggest that familial factors may interact with childhood maltreatment-associated insular structural differences to increase alcohol use. It is possible that FH+ individuals possess additional brain differences (e.g. white matter) not elucidated in the current study that decrease these individual’s ability to compensate for GMV deficits. Lower insula GMV was also associated with greater frequency of cannabis use over the past month. Unfortunately, the small sample size of individuals who used cannabis prevented us from investigating group by GMV interactions. Not only has recent work found the insula to play a key role in the development of addiction through its involvement in drug-craving and -seeking, but studies have also suggested insula abnormalities may stem from genetic, environmental, or developmental factors (or their combination) that precede onset of problematic substance use.

Interestingly, childhood maltreatment was not directly related to alcohol/cannabis use. While we cannot infer causality from this study, it is possible early life stress is indirectly associated with greater alcohol use, especially in those with greater genetic risk for bipolar disorder, and greater maltreatment-related differences in the brain—previously reported in bipolar disorder—may emerge over time. Additionally, a more enriched genetic risk group (i.e., presence of prodromal symptoms or identified through genetic testing) may reveal more robust results. Further supporting this are prior studies suggesting unipolar depression family history by ELS interactions on neural phenotypes and gene by ELS interactions on risk for, and symptom severity in, bipolar disorder. Interestingly, the low risk FH+ subgroup (FH+DEP−) exhibited a positive relationship between

| Table 3. | Insula gray matter volume in relation to alcohol/cannabis use patterns. Relations between insula gray matter volume (GMV) with alcohol and cannabis use measures. Analyses with alcohol measures as the dependent variable were performed across all participants (bipolar disorder family history negative (FH−), N = 25; bipolar disorder family history positive (FH+), N = 17) who completed the Timeline Follow Back and reported lifetime alcohol use, using GMV extracted from clusters showing a significant negative relationship with Childhood Trauma Questionnaire (CTQ) total score. Analysis with the cannabis measure as the dependent variable was performed only in past month cannabis user (FH−: N = 6, FH+: N = 7). Results are reported for the overall models, the family history group by insula GMV interaction, and the alcohol/cannabis use factors within each model. SE = standard error. |
|---------------------------------|-------------------------------------------------|-----------------|-----------------|-----------------|
| **Insula gray matter volume (GMV): average drinks/drinking day** | **t Ratio** | **SE** | **p value** |
| Family history group by insula GMV interaction on average drinks/drinking day | −2.3 | 1.2 | 0.03 |
| Model summary | F(3,49) = 2.9, p = 0.02, R² = 0.3 |
| FH+: average drinks/drinking day | 2.8 | 1.3 | 0.02 |
| Model summary | F(3,14) = 10.9, p = 0.0007, R² = 0.7 |
| FH−: average drinks/drinking day | 0.4 | 2.1 | 0.7 |
| Model summary | F(3,24) = 0.3, p = 0.8, R² = 0.04 |
| **Insula gray matter volume (GMV): maximum number of cannabis use days/weeks** | **t Ratio** | **SE** | **p value** |
| Maximum number of cannabis use days/week | −3.3 | 0.8 | 0.01 |
| Model summary | F(3,12) = 5.1, p = 0.02, R² = 0.6 |

For the overall models, the family history group by insula GMV interaction, and the alcohol/cannabis use factors within each model. SE = standard error.
childhood maltreatment and several GMV clusters in the ventral, rostral, and dorsal prefrontal cortex. While speculative, increased GMV in FH+ DEP− individuals may be neuroprotective. In fact, work has suggested neuroprotective mechanisms may prevent development of illness in asymptomatic individuals with bipolar familial risk54,55. Additionally, recent longitudinal work has indicated neural markers of risk and resilience in individuals with familial risk for bipolar disorder36. Future longitudinal work examining interactions between childhood maltreatment, familial risk, and substance use, and how associated brain changes relate to development of problematic substance use and neural trajectories, is critically needed to understand mechanisms and familial factors that confer risk for psychopathology.

Limitations. Findings from this preliminary cross-sectional study should be interpreted with caution due to a relatively small sample size and heterogeneous FH+ group characteristics. Causation cannot be determined without within subject experimental designs that directly link neuroanatomical differences to outcomes over time. Likewise, while GMV changes may contribute to risky alcohol use patterns in those with familial risk for
were considered significant at p < 0.005 uncorrected in hypothesized regions, and we did not correct for multiple
for a sensitivity analysis following a significant subgroup by CTQ interaction on GMV. Neuroimaging results
by depression history) did not significantly differ on these familial factors and we were able to match CTQ scores
other than bipolar disorder, but the FH− group had lower CTQ total scores compared to the FH+ group. The FH+
future studies, as previously suggested18,35. However, by not using a more conservative correction method there is
comparisons when looking at childhood maltreatment and GMV relations with a priori substance use variables.
Results are reported for the overall model for each cluster, and the GMV factor within each model for each cluster.

Table 4. Areas of gray matter volume showing a significant FH+ subgroup (FH+DEP− vs. FH+DEP+) by Childhood Trauma Questionnaire total score interaction. Brodmann Area and Montreal Neurological Institute space coordinates for clusters showing a significant FH+ subgroup by Childhood Trauma Questionnaire (CTQ) total score interaction. Using extracted gray matter volume (GMV) from these clusters, relations between CTQ total score and extracted GMV were modeled stratified by bipolar disorder family history positive (FH+) subgroups [FH+ individuals without a history of unipolar depression (FH+DEP−); FH+ individuals with a history of unipolar depression (FH+DEP+)] while covarying biological sex. Results are reported for the overall model for each cluster, and the GMV factor within each model for each cluster.

| Cluster localization and MNI coordinates at cluster peak | FH+DEP− (N = 9) | FH+DEP+ (N = 12) |
|----------------------------------------------------------|-----------------|-----------------|
|                                                          | t Ratio | SE    | p-value | t Ratio | SE    | p-value |
| Left Brodmann Area 11 x = −18 mm, y = 23 mm, z = 21 mm, clusters = 21 voxels | 3.16 | 0.002 | 0.02 | −3.45 | 0.0065 | 0.007 |
| Left Brodmann Area 11 x = −15 mm, y = 11 mm, z = −15 mm, clusters = 81 voxels | 2.9 | 0.001 | 0.03 | −3.6 | 0.0085 | 0.006 |
| Left Brodmann Area 47 x = −44 mm, y = 42 mm, z = −14 mm, clusters = 295 voxels | 3.9 | 0.001 | 0.008 | −5.0 | 0.0065 | 0.008 |
| Right Brodmann Area 11 x = 5 mm, y = 50 mm, z = −18 mm, clusters = 26 voxels | 2.2 | 0.001 | 0.07 | −4.9 | 0.0085 | 0.0008 |
| Right Brodmann Area 11 x = 9 mm, y = 12 mm, z = −14 mm, clusters = 23 voxels | 1.8 | 0.001 | 0.12 | −4.6 | 0.0006 | 0.001 |
| Right Brodmann Area 47 x = 41 mm, y = 27 mm, z = −5 mm, clusters = 67 voxels | 2.4 | 0.001 | 0.05 | −5.5 | 0.0007 | 0.0004 |
| Left Brodmann Area 10 x = −12 mm, y = 62 mm, z = −8 mm, clusters = 110 voxels | 5.11 | 0.0006 | 0.002 | −5.7 | 0.0004 | 0.0003 |
| Left Brodmann Area 10 x = −17 mm, y = 48 mm, z = 14 mm, clusters = 34 voxels | 3.4 | 0.001 | 0.02 | −2.4 | 0.0084 | 0.04 |
| Right Brodmann Area 10 x = 39 mm, y = 47 mm, z = −12 mm, clusters = 20 voxels | 2.9 | 0.001 | 0.03 | −3.2 | 0.0087 | 0.01 |
| Right Brodmann Area 46 x = 50 mm, y = 38 mm, z = 9 mm, clusters = 444 voxels | 2.9 | 0.002 | 0.03 | −4.8 | 0.0007 | 0.001 |
| Right Brodmann Area 10 x = 9 mm, y = 60 mm, z = 17 mm, clusters = 70 voxels | 2.1 | 0.002 | 0.09 | −4.4 | 0.0005 | 0.002 |
| Left Insula x = −44 mm, y = 6 mm, z = 8 mm, clusters = 864 voxels | 3.1 | 0.002 | 0.02 | −3.9 | 0.0008 | 0.003 |
| Right Insula x = 36 mm, y = 17 mm, z = −6 mm, clusters = 77 voxels | 2.7 | 0.001 | 0.04 | −4.0 | 0.0008 | 0.0003 |

bipolar disorder, it is also possible that individuals with familial risk may be more vulnerable to the negative
consequences of alcohol use which in turn may contribute to brain differences. This study also did not investigate
age of childhood maltreatment onset or duration. Differences in ELS severity, onset, and duration could have
contributed to results27, and future studies should incorporate these maltreatment factors.

We recruited a generalizable comparison group, which included some with family history of psychopathology
other than bipolar disorder, but the FH+ group had lower CTQ total scores compared to the FH+ group. The FH+ group
also had a greater prevalence of family history of anxiety disorders, compared to the FH− group; hence
results may not be specific only to familial risk for bipolar disorder. However, the two FH+ subgroups (stratified
by depression history) did not significantly differ on these familial factors and we were able to match CTQ scores
for a sensitivity analysis following a significant subgroup by CTQ interaction on GMV. Neuroimaging results
were considered significant at p < 0.005 uncorrected in hypothesized regions, and we did not correct for multiple
comparisons when looking at childhood maltreatment and GMV relations with a priori substance use variables.
These thresholds were set to avoid strict correction and to minimize type II errors and generate hypotheses for
future studies, as previously suggested18,35. However, by not using a more conservative correction method there is
greater risk for type I errors. Findings should therefore be considered hypothesis generating and interpreted with
cautions. Future longitudinal studies with larger sample sizes, more comprehensive assessment of maltreatment—
including onset and duration—and more homogeneous familial risk groups, are needed to confirm and extend
findings. Additionally, this work would benefit from examining individuals’ genetic loading and incorporating
other emerging genetic methods, including investigation of polygenic risk scores and epigenetic modifications.
Conclusion
Our findings are concordant with the current literature suggesting that childhood maltreatment is inversely related to prefrontal-paralimbic GMV. While preliminary, results suggest familial factors may relate to alcohol use patterns following childhood maltreatment. Not all individuals who exhibit childhood maltreatment-related GMV abnormalities develop psychopathology, and more research on factors that contribute to different clinical outcomes following maltreatment is critically needed for early intervention and prevention strategies.

Received: 4 March 2020; Accepted: 21 December 2020
Published online: 08 January 2021

References
1. Anda, R. F. et al. The enduring effects of abuse and related adverse experiences in childhood. *Eur. Arch. Psychiatry Clin. Neurosci.* 174–186 (2006).
2. Kessler, R. C. et al. Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. *Br. J. Psychiatry* 197, 378–385. https://doi.org/10.1192/bjp.bp.109.080499 (2010).
3. Eitan, B., Henry, C., Bellivier, F., Mathieu, F. & Leboyer, M. Beyond genetics: childhood affective trauma in bipolar disorder. *Bipolar Disord.* 10, 867–876. https://doi.org/10.1111/bip.12355 (2008).
4. Strakowski, S. M. et al. The functional neuroanatomy of bipolar disorder: a consensus model. *Bipolar Disord.* 14, 313–325. https://doi.org/10.1111/j.1399-5618.2011.01022.x (2012).
5. Volkow, N. D., Wang, G. J., Fowler, J. S. & Tomasi, D. Addiction circuitry in the human brain. *Ann. Rev. Pharmacol. Toxicol.* 52, 321–336. https://doi.org/10.1146/annurev-pharmaco-010611-134625 (2012).
6. Trager, M. H., Samson, J. A., Anderson, C. M. & Ohashi, K. The effects of childhood maltreatment on brain structure, function and connectivity. *Nat. Rev. Neurosci.* 17, 652–666. https://doi.org/10.1038/nrn.2016.111 (2016).
7. Souza-Queiroz, J. et al. Childhood trauma and the limbic network: A multimodal MRI study in patients with bipolar disorder and controls. *J. Affect. Disord.* 200, 159–164. https://doi.org/10.1016/j.jad.2016.04.038 (2016).
8. Janiri, D. et al. Amygdala and hippocampus volumes are differentially affected by childhood trauma in patients with bipolar disorders and healthy controls. *Bipolar Disord.* 19, 353–362. https://doi.org/10.1111/bip.12357 (2017).
9. Poletti, S. et al. Adverse childhood experiences influence the detrimental effect of bipolar disorder and schizophrenia on cortico-limbic grey matter volumes. *J. Affect. Disord.* 189, 290–297. https://doi.org/10.1016/j.jad.2015.09.049 (2016).
10. Hafeman, D. M., Chang, K. D., Garrett, A. S., Sanders, E. M. & Phillips, M. L. Effects of medication on neuroimaging findings in bipolar disorder: An updated review. *Bipolar Disord.* 14, 375–410. https://doi.org/10.1111/j.1399-5618.2012.01023.x (2012).
11. Kalmar, J. H. et al. Preliminary evidence for progressive prefrontal abnormalities in adolescents and young adults with bipolar disorder. *J. Int. Neuropsychol. Soc.* 15, 476–481. https://doi.org/10.1017/s1355617709090584 (2009).
12. van der Schot, A. C. et al. Genetic and environmental influences on focal brain density in bipolar disorder. *Brain* 133, 3080–3092. doi:10.1093/brain/awq236 (2010).
13. Kozicky, J. M. et al. Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome. *Bipolar Disord.* 18, 511–519. https://doi.org/10.1111/bip.12437 (2016).
14. Rao, U. et al. Hippocampal changes associated with early-life adversity and vulnerability to depression. *Biol. Psychiatry* 67, 357–364. doi:10.1016/j.biopsych.2009.10.017 (2010).
15. Kirsch, D., Deneroff, C. M. & Lippard, E. T. Early life stress and substance use disorders: underlying neurobiology and pathways to adverse outcomes. *Advers. Resil. Sci.* 1, 29–47. https://doi.org/10.1007/s42844-020-00005-7 (2020).
16. Wu, N. S., Schaier, L. C., Dellor, E. & Grella, C. Childhood trauma and health outcomes in adults with comorbid substance abuse and mental health disorders. *Addict. Behav.* 35, 68–71. https://doi.org/10.1016/j.addbeh.2009.09.003 (2010).
17. Goldstein, R. Z. & Volkow, N. D. Dysfunction of the prefrontal cortex in addiction: Neuroimaging findings and clinical implications. *Nat. Rev. Neurosci.* 12, 652–669. https://doi.org/10.1038/nrn3119 (2011).
18. Lippard, E. T. et al. Brain circuitry associated with the development of substance use in bipolar disorder and preliminary evidence for sexual dimorphism in adolescents. *J. Neurosci. Res.* 95, 777–791. https://doi.org/10.1002/jnr.23901 (2017).
19. Carmiol, N. et al. Shared genetic factors influence risk for bipolar disorder and alcohol use disorders. *Eur Psychiatry* 29, 282–287. https://doi.org/10.1016/j.eurpsyc.2013.10.001 (2014).
20. Muslimer, K. L. et al. Association of polygenic liabilities for major depression, bipolar disorder, and schizophrenia with risk for depression in the Danish population. *JAMA Psychiatry* 76, 516–525. https://doi.org/10.1001/jamapsychiatry.2018.4166 (2019).
21. Brady, K. T. & Sinha, R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. *Annu. Rev. Psychiatry* 162, 1483–1493. https://doi.org/10.1176/appi.ajp.162.8.1483 (2005).
22. Duffy, A. et al. The developmental trajectory of bipolar disorder. *Br. J. Psychiatry* 204, 122–128. https://doi.org/10.1192/bjp.bp.113.126706 (2014).
23. Greene, D. J., Black, J. J. & Schlaggar, B. L. Considerations for MRI study design and implementation in pediatric and clinical populations. *Dev. Cogn. Neurosci.* 18, 101–112. https://doi.org/10.1016/j.dcn.2015.12.003 (2016).
24. Manela, A. et al. Altered amygdala-prefrontal response to facial emotion in offspring of parents with bipolar disorder. *Brain* 138, 2777–2790. https://doi.org/10.1093/brain/awv176 (2015).
25. First MB, W. J., Karg RS, Spitzer RL. *Structured Clinical Interview for DSM—5—Research Version* (SCID-5 for DSM-5, Research Version: SCID-5-RV). (American Psychiatric Association, 2015).
26. Corporation, P. Wechsler Abbreviated Scale of Intelligence Manual. (TXHarcout Brace and Company, 1999).
27. Andreasen, N. C., Endicott, J., Spitzer, R. L. & Winokur, G. The family history method using diagnostic criteria: Reliability and validity. *Arch. Gen. Psychiatry* 34, 1229–1235. https://doi.org/10.1001/archpsyc.1977.0177022011013 (1977).
28. Bernstein, D., Fink, L. *Childhood Trauma Questionnaire: A Retrospective Self-report Questionnaire and Manual*. (Psychological Corp, 1998).
29. Arrowb, A. Relationships between childhood maltreatment, adult health and psychiatric outcomes, and medical utilization. *J. Clin. Psychiatry* 65(Suppl 12), 10–15 (2004).
30. Green, J. G. et al. Childhood adversities and adult psychiatric disorders in the national comorbidity survey replication I: Associations with first onset of DSM-IV disorders. *Arch. Gen. Psychiatry* 67, 113–123. https://doi.org/10.1001/archgenpsychiatry.2009.186 (2010).
31. Elton, A. et al. Childhood maltreatment is associated with a sex-dependent functional reorganization of a brain inhibitory control network. *Hum. Brain Mapp.* 35, 1654–1667. https://doi.org/10.1002/hbm.22280 (2014).
32. Sobell, L. et al. *Timeline follow-back, M* (Humana Press, Totowa, 1992).
33. Hjorthøj, C. R., Hjorthøj, A. R. & Nordentoft, M. *Validity of Timeline Follow-Back for self-reported use of cannabis and other illicit substances—systematic review and meta-analysis*. *Addict. Behav.* 37, 225–233. https://doi.org/10.1016/j.addbeh.2011.11.025 (2012).
34. Edmiston, E. E. et al. Corticostriatal-limbic gray matter morphology in adolescents with self-reported exposure to childhood maltreatment. Arch. Pediatr. Adolesc. Med. 165, 1069–1077. https://doi.org/10.1001/archpediatrics.2011.565 (2011).
35. Lieberman, M. D. & Cunningham, W. A. Type I and Type II error concerns in fMRI research: Re-balancing the scale. Soc. Cogn. Affect. Neurosci. 4, 423–428. https://doi.org/10.1093/scan/nsp052 (2009).
36. Hawkins, J. D. et al. Exploring the effects of age of alcohol use initiation and psychosocial risk factors on subsequent alcohol misuse. J. Stud. Alcohol 58, 280–290. https://doi.org/10.15288/jsa.1997.58.280 (1997).
37. Hawkins, R. W., Heeren, T. & Winter, M. R. Age of alcohol-dependence onset: Associations with severity of dependence and seeking treatment. Pediatrics 118, e755-763. https://doi.org/10.1542/peds.2006-0223 (2006).
38. Warner, L. A., White, H. R. & Johnson, V. Alcohol initiation experiences and family history of alcoholism as predictors of problem-drinking trajectories. J. Stud. Alcohol Drugs 68, 56–65. https://doi.org/10.15288/jstud.2007.68.56 (2007).
39. Lee, S. H., Lee, B. C., Kim, J. W., Yi, I. S. & Choi, I. G. Association between alcoholism family history and alcohol screening scores among alcohol-dependent patients. Clin. Psychopharmacol. Neurosci. 11, 89–95. https://doi.org/10.9758/cpn.2013.11.2.89 (2013).
40. Xue, G., Lu, Z., Levin, I. P. & Bechara, A. The impact of prior risk experiences on subsequent risky decision-making: The role of the insula. Neuroimage 50, 709–716. https://doi.org/10.1016/j.neuroimage.2009.12.097 (2010).
41. Jakubczak, A. et al. The association between impulsivity, emotion regulation, and symptoms of alcohol use disorder. J. Subst. Abuse Treat. 91, 49–56. https://doi.org/10.1016/j.jsat.2018.05.004 (2018).
42. Goldstein, B. L., Velvis, V. P. & Parikh, S. V. The association between moderate alcohol use and illness severity in bipolar disorder: a preliminary report. J. Clin. Psychiatry 67, 102–106. https://doi.org/10.4088/jcp.v67n0114 (2006).
43. Stevelink, R. et al. Childhood abuse and white matter integrity in bipolar disorder patients and healthy controls. Eur. Neuropsychopharmacol. 28, 807–817. https://doi.org/10.1016/j.euroneuro.2018.05.003 (2018).
44. Nacyp, N. H., Gazznick, N., Tanel, D. & Rechera, A. The insula: a critical neural substrate for craving and drug seeking under conflict and risk. Ann. N. Y. Acad. Sci. 1316, 53–70. https://doi.org/10.1111/nyas.12415 (2014).
45. Itain, B. et al. Interaction between SLCA6A4 promoter variants and childhood trauma on the age at onset of bipolar disorder. Sci. Rep. 5, 16301. https://doi.org/10.1038/srep16301 (2015).
46. Coryell, W. et al. Bipolar affective disorder and high achievement: A familial association. Am. J. Psychiatry 146, 983–988. https://doi.org/10.1176/ajp.146.8.983 (1989).
47. Swann, A. C. What is bipolar disorder?. Am. J. Psychiatry 163, 177–179. https://doi.org/10.1176/appi.ajp.163.2.177 (2006).
48. Nimarko, A. F., Garrett, A. S., Carlson, G. A. & Singh, M. K. Neural correlates of emotion processing predict resilience in youth at familial risk for mood disorders. Dev. Psychopathol. 31, 1037–1052. https://doi.org/10.1017/S0954579419000579 (2019).
49. Herzog, J. I. et al. Influence of severity of type and retrospectively reported childhood maltreatment on female amygdala and hippocampal volume. Sci. Rep. 10, 1903. https://doi.org/10.1038/s41598-020-57490-0 (2020).

Acknowledgements

The authors were supported by research grants from the Jones/Bruce Fellowship from the Waggoner Center on Alcohol and Addiction Research (DEK, VT), T32 AA07471 (VT), the National Institute of Health Grants MH117293 and AA024933 (CN), R01 AA020637 (KF), R21 AA027884 (ETCL), and K01 AA027573 (ETCL). We acknowledge the contribution of Sara Budjack for initial participant recruitment and data collection.

Author contributions

Study concept and design: D.E.K. and E.T.C.L. Data acquisition: D.E.K., V.T., S.R., W.A.W., E.T.C.L. Data analysis and interpretation: D.E.K. and E.T.C.L. Drafting of manuscript: D.E.K. and E.T.C.L. Critical revisions of manuscript: D.E.K., V.T., S.R., W.A.W., C.N., K.F., S.M.S., and E.T.C.L. Statistical analyses: D.E.K. and E.T.C.L. Obtained study funding: E.T.C.L. Administrative, technical, and material support: D.E.K., V.T., S.R., W.A.W., C.N., K.F., S.M.S., and E.T.C.L. Study supervision: E.T.C.L.

Competing interests

We do not believe that any of these relationships could influence the reported results but we report them for transparency. SMS consults for Sunovian and Otsuka and holds research grants with Janssen. ETCL received funding for a Janssen-sponsored study through UT. In the last 3 years, CN has consulted to Xhale, Takeda, Taisho Pharmaceutical Inc., Signant, Sunovion Pharmaceuticals Inc., Janssen Research & Development, Magstim, Inc., Navitor Pharmaceuticals, Inc., Actify Neurotherapies, Intra-Cellular Therapies, Inc. CN is a Stockholder of Xhale, Celgene, Seattle Genetics, Abbvie, Antares, BI Gen Holdings, Inc., Conceptor Therapeutics Pharmaceuticals Company, TC MSO, Inc., and Trends in Pharma Development, LLC. CN is a member of the scientific advisory boards of the Brain and Behavior Research Foundation (BBRF), Xhale, Anxiety Disorder Association of America (ADAA), Skyland Trail, Signant Health, Laureate Institute for Brain Research (LJBR), Inc. and on the board of directors of AFSP, Gratitude America, Chale Smart and ADAA. CN has had income sources or equity of 10,000 USD or more from American Psychiatric Publishing, Xhale, Signant Health, CME Outfitters, Actify Neurotherapies, Intra-Cellular Therapies, Inc., and Magstim. CN holds the following patents: method and devices for transdermal delivery of lithium (US 6375990B1), Method of assessing antidepressant drug therapy via transport.
inhibition of monoamine neurotransmitter by ex vivo assay (US 7148027B2), and Compounds, Compositions, Methods of Synthesis, and Methods of Treatment (CRF Receptor Binding Ligand) (US 8551996 B2). All other authors declare no competing interests.

**Additional information**

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1038/s41598-020-80407-w.

**Correspondence** and requests for materials should be addressed to E.T.C.L.

**Reprints and permissions information** is available at www.nature.com/reprints.

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

[Open Access] This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021